Matthew Carr With Emerald Health Sciences’ Dr. Avtar Dhillon on CannaBiz Now!

written by Matthew Carr
Thursday, November 15, 2018

This is individual research and does not constitute investment advice.

There is no industry changing as rapidly – or as unevenly – as cannabis.

After the midterm elections, there are now 32 states that have legalized medical marijuana and 10, including the District of Columbia, that have passed adult-use measures.

The U.S. market continues to expand.

And with former U.S. Attorney General Jeff Sessions – a longtime cannabis opponent – out of the way, this expansion is poised to accelerate.

Then we have Canada… Our neighbor to the north began legal adult-use sales last month.

There was also the U.K.’s recent approval of medical cannabis… Germany’s blossoming medical market… and measures in Israel, Australia and more than two dozen other countries.

The world is rushing headlong into what I believe will be a $200 billion market by 2030.

Because of this rapid evolution, the constant mergers and acquisitions, and the bevy of opportunities – and pitfalls – that appear each week, we’re launching a new series: CannaBiz Now!

In this weekly video segment, I’ll talk to cannabis CEOs, business leaders, medical professionals and industry experts to keep investors up to date on this rapidly changing sector.

These industry insiders will share their experiences.

They’ll provide us with insights from the ground floor, from sales to regulations to the latest trends.

And they’ll inform investors of all things related to the cannabis business.

Our first guest is Dr. Avtar Dhillon, a life sciences entrepreneur with more than three decades of experience. He is the chairman of the newly formed Cannabis Council of Canada and executive chairman of Emerald Health Sciences. Investors are likely familiar with one of the company’s publicly traded arms, Emerald Health Therapeutics (OTC: EMHTF).

Today, he shares with us what he sees ahead for the medical marijuana industry, as well as areas of treatment that excite him the most.

Enjoy this new offering!

Good investing,

Matthew